163 related articles for article (PubMed ID: 32339417)
1. Fibrinolysis and tranexamic acid: mechanistic principles.
Draxler DF; Medcalf RL
ANZ J Surg; 2020 Apr; 90(4):410-411. PubMed ID: 32339417
[No Abstract] [Full Text] [Related]
2. Tranexamic acid in patients with multiple injuries: good, elegant, and cheap?
Egea-Guerrero JJ; Ballesteros MÁ; Quintana-Díaz M
Emergencias; 2019 Ago; 31(4):281-282. PubMed ID: 31347809
[No Abstract] [Full Text] [Related]
3. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
Barrett CD; Moore HB; Kong YW; Chapman MP; Sriram G; Lim D; Moore EE; Yaffe MB
J Trauma Acute Care Surg; 2019 Jan; 86(1):101-107. PubMed ID: 30575685
[TBL] [Abstract][Full Text] [Related]
4. Basis of antifibrinolytic therapy.
Prentice CR
J Clin Pathol Suppl (R Coll Pathol); 1980; 14():35-40. PubMed ID: 6159375
[No Abstract] [Full Text] [Related]
5. Clinical relevance and practical assessment of fibrinolysis shutdown.
Moore HB; Moore BA; Sauaia A; Moore EE
ANZ J Surg; 2020 Apr; 90(4):413-414. PubMed ID: 31535453
[No Abstract] [Full Text] [Related]
6. Perspectives on tranexamic acid in surgery.
Balogh ZJ; King KL
ANZ J Surg; 2020 Apr; 90(4):409. PubMed ID: 32339435
[No Abstract] [Full Text] [Related]
7. Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid.
Moore EE; Moore HB; Gonzalez E; Chapman MP; Hansen KC; Sauaia A; Silliman CC; Banerjee A
J Trauma Acute Care Surg; 2015 Jun; 78(6 Suppl 1):S65-9. PubMed ID: 26002266
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trials and Cochrane analyses versus precision-based medicine for tranexamic acid and viscoelastic testing in trauma.
Walsh M; Grisoli A; Zackariya N; Thomas AV; Sualeh A
ANZ J Surg; 2020 Apr; 90(4):415-416. PubMed ID: 32339433
[No Abstract] [Full Text] [Related]
9. Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts.
Hayward CPM; Tasneem S; Rivard GE
Int J Lab Hematol; 2020 Dec; 42(6):e274-e276. PubMed ID: 33205919
[No Abstract] [Full Text] [Related]
10. Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography?
Moore HB; Moore EE; Chapman MP; Hansen KC; Cohen MJ; Pieracci FM; Chandler J; Sauaia A
J Am Coll Surg; 2019 Jul; 229(1):92-101. PubMed ID: 30936005
[TBL] [Abstract][Full Text] [Related]
11. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
He S; Johnsson H; Zabczyk M; Hultenby K; Wallén H; Blombäck M
Thromb Haemost; 2014 Mar; 111(3):417-28. PubMed ID: 24196490
[TBL] [Abstract][Full Text] [Related]
12. Computational model of tranexamic acid on urokinase mediated fibrinolysis.
Wu TB; Orfeo T; Moore HB; Sumislawski JJ; Cohen MJ; Petzold LR
PLoS One; 2020; 15(5):e0233640. PubMed ID: 32453766
[TBL] [Abstract][Full Text] [Related]
13. [Tranexamic acid--an old drug in a new costume. Multinational studies and new texts provide a boost for the antifibrinolytic agent].
Tengborn L; Berntorp E
Lakartidningen; 2013 Aug 21-Sep 3; 110(34-35):1458-9. PubMed ID: 24044180
[No Abstract] [Full Text] [Related]
14. Role of fibrinogen in massive injury.
Maung AA; Kaplan LJ
Minerva Anestesiol; 2014 Jan; 80(1):89-95. PubMed ID: 23857437
[TBL] [Abstract][Full Text] [Related]
15. Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation.
Kaspar M; Ramsay MA; Nguyen AT; Cogswell M; Hurst G; Ramsay KJ
Anesth Analg; 1997 Aug; 85(2):281-5. PubMed ID: 9249100
[TBL] [Abstract][Full Text] [Related]
16. Does Oral or Topical Tranexamic Acid Control Bleeding From Epistaxis?
Bridwell RE; April MD; Long B
Ann Emerg Med; 2019 Aug; 74(2):300-302. PubMed ID: 31060746
[No Abstract] [Full Text] [Related]
17. TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial.
Ducloy-Bouthors AS; Jeanpierre E; Saidi I; Baptiste AS; Simon E; Lannoy D; Duhamel A; Allorge D; Susen S; Hennart B
Trials; 2018 Mar; 19(1):149. PubMed ID: 29490690
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial.
Bouthors AS; Hennart B; Jeanpierre E; Baptiste AS; Saidi I; Simon E; Lannoy D; Duhamel A; Allorge D; Susen S
Trials; 2018 Mar; 19(1):148. PubMed ID: 29490682
[TBL] [Abstract][Full Text] [Related]
19. Temporally and regionally disparate differences in plasmin activity by tranexamic acid.
Reust DL; Reeves ST; Abernathy JH; Dixon JA; Gaillard WF; Mukherjee R; Koval CN; Stroud RE; Spinale FG
Anesth Analg; 2010 Mar; 110(3):694-701. PubMed ID: 20185649
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of synthetic antifibrinolytic agents during liver transplantation.
Kang Y
Semin Thromb Hemost; 1993; 19(3):258-61. PubMed ID: 8362255
[No Abstract] [Full Text] [Related]
[Next] [New Search]
